GMAB News and Press, Genmab A/S From 07/20/23

Company Announcement Net sales of DARZALEX ® in the second quarter of 202 3 totaled USD 2,431 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; July 20...

2023-07-16 20:14:12 ET UK-based HSBC initiated coverage of 19 major biopharma stocks this past week, labeling Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ), Merck KGaA ( OTCPK:MKGAF ) ( OTCPK:MKKGY ) and Lonza ( OTCPK:LZAGY ) ( OTCPK:LZAGF ) as potential comeback stories, wh...

2023-07-12 07:51:55 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Artificial intelligence ( AI ) has become an invaluable tool for investors seeking opportunities in the stock market. Its ability to analyze large amounts of data and recognize patterns m...

2023-07-02 09:30:00 ET Epcoritamab, a cancer drug co-developed by AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) , was recently given the green light by the Food and Drug Administration to be used as a treatment for adults with relapsed or refractory (R/R) diffuse large B-cel...

2023-06-29 10:05:50 ET Summary Genmab's stock has seen negative price action despite the FDA approval of its drug, Epcoritamab, for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The market has already priced in the approval, and the drug faces a competitive landscape ...

Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage with global regulatory authorities to discuss next steps Data from the clinical trial will be presented at a future medical meeting Follicular Ly...

Genmab A/S (Nasdaq: GMAB) today announced that epcoritamab, a T-cell engaging bispecific antibody, has been added to the National Comprehensive Cancer Network ® (NCCN ® ) Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for “B-cell Lymphomas&#x...

Results from phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab in combination with rituximab-lenalidomide (R2) showed a 98 percent overall response rate (ORR), 87 percent complete metabolic response (CMR) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) ...

2023-05-29 06:15:24 ET Summary Shares of antibody drug conjugate concern ADC Therapeutics SA are down 95% from their all-time high set in mid-2020 as tepid upside to Zynlonta sales and Cami program uncertainty. The company does have two licensing deals inked for Zynlonta and is se...

Oral presentations will highlight epcoritamab-bysp in combination with rituximab-lenalidomide (R2) in high-risk follicular lymphoma Poster presentations will highlight epcoritamab in lymphoma across multiple lines of therapy and histologies where high unmet needs exist Gen...